Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal MelanomaRichard D. Carvajal, Gary K. Schwartz, Jeffrey A. Sosman et al.|JAMA|2014Cited by 429
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Andrew Haydon et al.|The Lancet Oncology|2021Cited by 389
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Daniil Stroyakovskiy, Corneel Coens et al.|The Lancet Oncology|2021Cited by 72